Multiparametric MRI for Characterization of Hepatocellular Carcinoma

Launched by UNIVERSITY HOSPITAL MUENSTER · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the use of a special type of imaging called multiparametric MRI to better understand and manage hepatocellular carcinoma (HCC), which is a type of liver cancer. The researchers want to see if these advanced MRI scans can help doctors make more accurate diagnoses and create personalized treatment plans without needing invasive procedures. The study is taking place at a university center in Germany and is currently looking for adult patients who have either been diagnosed with HCC or are suspected of having it.

To be eligible for this trial, participants need to be at least 18 years old, have a confirmed or suspected diagnosis of HCC, and be scheduled to receive specific treatments as part of their regular care. They must also be able to undergo an MRI safely. Participants will have standardized MRI scans, and the results will be compared with their overall health, treatment responses, and other important factors. It's important to note that no new medications or treatments will be provided as part of this study; it’s focused solely on gathering information to improve future care for people with HCC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Confirmed or suspected diagnosis of HCC
• • Scheduled to receive TACE or SIRT as part of standard clinical care
• • Eligibility for liver MRI
• • Willing and able to provide written informed consent
• Exclusion Criteria:
• • Contraindications to MRI (e.g., pacemakers, ferromagnetic implants, severe claustrophobia)
• • Known allergy or intolerance to gadolinium-based contrast agents
• • Renal insufficiency with estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²
• • Pregnancy or breastfeeding
• • Inability to provide informed consent